Generics, Super-Generics and Patent Strategies
10th to 11th May 2010, Crowne Plaza Hotel - St James, London

The worldwide generics industry has seen strong growth in recent times as the demand for affordable treatment has increased worldwide. In addition to this, from 2008-2010 a total of 36 key drugs are expected to lose patent protection providing a huge opportunity for the sector to expand further.

Join us for SMi's 13th annual Generics, Super-Generics and Patent Strategies and discover the future of the generics market. Hear experts in the field discuss the latest patent strategies, regulatory updates and growth strategies that will be key to the future of the industry.

Key topics will include:

• Examine the legal framework and litigation mechanics in both the EU and US
• Latest legislative and regulatory updates in generics and biosimilars
• Identify key growth areas and methods to take advantage of these
• M&A activities and their implications
• New business models
• Emerging markets
• R&D in generics

This year’s speaker line-up includes:

• Bill Haddad, Chairman & CEO, Biogenerics
• John Beighton , Generics Industry Consultant & ex-Vice President, Global Business Optimisation, Teva
• Shazli Ahmed Khan, Manager, Strategy & Business Development, Pfizer Ltd
• Anders Fuglsang, Clinical & Regulatory Strategy Manager, Aeropharm

For more information please visit us at: http://www.smi-online.co.uk/2010generics7.asp
Alternatively, call: Zain Philbey on +44 0207 827 6722 or email on: zphilbey@smi-online.co.uk

2 day conference with 2 workshops available